Regeneron's COVID-19 antibodies breach a new frontier by cutting deaths in some hospitalized patients Amazon kicks off new role as diagnostics provider by making COVID test available online 70% of employers say they won't mandate COVID vaccinations: Willis Towers Watson NIH antibody study suggests COVID-19 spread across U.S. earlier than originally known CDC's new guidance for treating COVID-19 long-haulers warns against relying on labs, imaging results alone While mRNA saved the COVID-19 day, GSK and Sanofi vaccines likely safe beyond pandemic: analysts Evotec wants to prevent the next COVID-19 crisis, and you could help COVID-19 tracker: Russia's Sputnik V authorization delayed in EU; Delta variant cases 'rapidly increasing' in U.S. BIO 2021: After COVID-19 showcased the power of science, J&J exec urges industry to start thinking 'cure' in cancer Molecular Partners prices $64M IPO, falling short of original goal Featured Story | By Kevin Dunleavy Hospitalized COVID-19 patients that haven't been able to generate their own antibody responses can benefit from Regeneron's antibody cocktail, a large new study found. The data could take REGEN-COV to a new group of patients—and a new source of sales. read more |
| |
|---|
|
| | Who’s Watching Your Clinical Trial Supply Chain? With the ever-increasing costs of clinical trials and the advantages of being first-to-market, it’s time to take a closer look at your supply chain to ensure it delivers with speed, efficiency, and quality — all within your budget. Learn about key strategies for mitigating risk in clinical trials. Learn more. |
Top Stories By Andrea Park Amazon has already changed the way we shop and filled our homes with “smart” gadgets, and now, the tech giant is looking to revolutionize the way we manage our health. read more By Paige Minemyer Employers are mulling vaccine requirements for certain workplace amenities, such as gyms and cafeterias, a new survey shows. read more By Andrea Park Though the first confirmed domestic case of COVID-19 was announced Jan. 21, 2020, new research from the NIH indicates that the coronavirus made its way to the U.S. shores well before that—at least as early as December 2019—reaching far beyond the initial hotspots of Washington state and New York. read more By Dave Muoio The guidance outlines the "broad spectrum" of symptoms these patients face after acute infection and advocates for patient-centered care approaches targeting quality of life and function. read more By Noah Higgins-Dunn Although the mRNA vaccines from Pfizer-BioNTech and Moderna have shown "astonishing" efficacy against COVID-19, the novel technology is "not a panacea" for other diseases, Jefferies analysts said in a note. That's good news for other vaccine developers, namely Sanofi and GlaxoSmithKline, they argue. read more By Kyle LaHucik German biotech-CRO hybrid Evotec is launching a new program linking up resources across the antiviral therapeutics development chain to fight the “permanent global threat" of a pandemic. read more By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner The European Union's approval for Russia's Sputnik V vaccine likely won't come until September at the earliest because of a missed June 10 deadline to submit data, sources tell Reuters. U.S. cases with the Delta variant first found in India are "rapidly increasing," a top health official warned. And more headlines. read more By Eric Sagonowsky Amid COVID-19 lockdowns, routine cancer screenings were put on the back burner. While that may be a short-term harm from the pandemic, the crisis also showed the world that science can solve tough problems, a Johnson & Johnson exec said, and that could bring long-term wins in oncology. read more By Nick Paul Taylor Molecular Partners has priced its IPO, setting it up to raise $63.8 million to fund work on oncology and infectious disease candidates. The IPO haul is set to fall well short of the original target after a five-day period in which the biotech’s share price in Switzerland fell 17%. read more |
